1000676-41-4

1000676-41-4 structure
1000676-41-4 structure
  • Name: Lirilumab
  • Chemical Name: Lirilumab
  • CAS Number: 1000676-41-4
  • Molecular Formula:
  • Molecular Weight:
  • Catalog: Research Areas Cancer
  • Create Date: 2018-07-10 05:14:16
  • Modify Date: 2025-09-08 08:15:09
  • Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research[1][2].

Name Lirilumab
Description Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research[1][2].
Related Catalog
In Vivo Lirilumab (intravenous injection; 15 mg/kg; once) treatment enhances survival rate of mice injected with tumor[2]. Animal Model: Rag1KO-Tg KIR mice injected with tumor cells[2] Dosage: 15 mg/kg Administration: intravenous injection; 15 mg/kg; once Result: Showed 6 of 7 mice survival over a 100-day period, whereas untreated or IC-treated mice all died.
References

[1]. Hanna GJ, et al. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Feb 1;28(3):468-478.

[2]. Kohrt HE, et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood. 2014 Jan 30;123(5):678-86.

No Any Chemical & Physical Properties
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.